# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.
The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a pre...
73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patien...
88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-neg...
administration in new Phase 2 dataCHICAGO, June 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today new data from the...
JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with...
https://www.youtube.com/watch?v=qCsEbq9SpsM